14亿美元!艾伯维收购Aliada,获得一款3pE-Aβ抗体,来自于强生授权

Medaverse
28 Oct 2024

10月28日,艾伯维(AbbVie)宣布以14亿美元全现金收购Aliada Therapeutics的所有未偿股权,Aliada正利用一种新型的血脑屏障(BBB)交叉技术开发新药,以解决具有挑战性的中枢神经系统(CNS)疾病。Aliada利用这种递送技术的主要研究资产ALIA-1758是一种正在开发的抗焦谷氨酸淀粉样蛋白β(3pE-Aβ)抗体,用于治疗阿尔茨海默病。该交易预计将于2024年第4季度...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10